Skip to content
Home » Oncology » Oncology – UTUC » Adjuvant intravesical therapy

Adjuvant intravesical therapy

Randomised level 1 data has shown that a single post-operative dose of intravesical chemotherapy reduces the risk of bladder tumour recurrence after neph-u.

ODMIT-C trial:

  • Bladder recurrence in the first year 28 % in control arm vs 16 % in mitomycin C arm

Ito (2013)

  • Single dose pirarubicin reduced bladder recurrence to 17 % at 2 years, vs 42 % in control arm

 

Strong recommendation in EAU guidelines for single dose intravesical chemotherapy to reduce bladder recurrence.

 

Logistics:

  • Perform cystogram around day 7 through catheter
  • If no leak, deliver 40 mg / 40 mL via catheter and leave to dwell for 2 hours prior to catheter removal
  • Mitomycin C works better in alkalinised urine – therefore should probably start oral Sodibic the day prior

 

GEMINI trial is recruiting to assess intra-operative filling of bladder with gemcitabine during nephroureterectomy, with drainage prior to bladder cuff excision.